AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2014
Dec 15, 2014
32254_dirs_2014-12-15_86308c4c-f373-45e8-9663-91b9e165300d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: pSivida Corp. (PSDV)
CIK: 0001314102
Period of Report: 2014-12-11
Reporting Person: Ashton Paul (Director, President and CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-12-11 | Employee Stock Option (right to buy) | $4.47 | A | 245000 | Acquired | 2024-07-15 | Common Stock (245000) | Direct |
Footnotes
F1: The option becomes exercisable in four equal annual installments beginning on July 15, 2015.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Apr 13
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7